Literature DB >> 20376439

Characterizing the anti-tumor function of adoptively transferred NK cells in vivo.

Hollie J Pegram1, Nicole M Haynes, Mark J Smyth, Michael H Kershaw, Phillip K Darcy.   

Abstract

Natural killer (NK) cells represent a promising cell type to utilize for effective adoptive immunotherapy. However, little is known about the important cytolytic molecules and signaling pathways used by NK cells in the adoptive transfer setting. To address this issue, we developed a novel mouse model to investigate the trafficking and mechanism of action of these cells. We demonstrate that methylcholanthrene-induced RKIK sarcoma cells were susceptible to NK cell-mediated lysis in vitro and in vivo following adoptive transfer of NK cells in C57BL/6 RAG-2(-/-)gammac(-/-) mice. Cytotoxic molecules perforin, granzymes B and M as well as the death ligand TRAIL and pro-inflammatory cytokine IFN-gamma were found to be important in the anti-tumor effect mediated by adoptively transferred NK cells. Importantly, we demonstrate that adoptively transferred NK cells could traffic to the tumor site and persisted in vivo which correlated with the anti-tumor effect observed. Overall, the results of this study have important implications for enhancing NK cell-based immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20376439     DOI: 10.1007/s00262-010-0848-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

Review 1.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

Review 2.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

3.  Densely granulated murine NK cells eradicate large solid tumors.

Authors:  Rebecca B Liu; Boris Engels; Ainhoa Arina; Karin Schreiber; Elizabeth Hyjek; Andrea Schietinger; David C Binder; Eric Butz; Thomas Krausz; Donald A Rowley; Bana Jabri; Hans Schreiber
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

Review 4.  Granzyme M: behind enemy lines.

Authors:  S A H de Poot; N Bovenschen
Journal:  Cell Death Differ       Date:  2014-01-10       Impact factor: 15.828

5.  Mouse granzyme A induces a novel death with writhing morphology that is mechanistically distinct from granzyme B-induced apoptosis.

Authors:  O Susanto; S E Stewart; I Voskoboinik; D Brasacchio; M Hagn; S Ellis; S Asquith; K A Sedelies; P I Bird; N J Waterhouse; J A Trapani
Journal:  Cell Death Differ       Date:  2013-06-07       Impact factor: 15.828

6.  Tumor-Associated T-Lymphocytes and Macrophages are Decreased in Endometrioid Endometrial Carcinoma with MELF-Pattern Stromal Changes.

Authors:  Dmitry Aleksandrovich Zinovkin; Md Zahidul Islam Pranjol; Il'ya Andreevich Bilsky; Valeriya Alexandrovna Zmushko
Journal:  Cancer Microenviron       Date:  2018-07-14

7.  Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis.

Authors:  S A H de Poot; K W Lai; L van der Wal; K Plasman; P Van Damme; A C Porter; K Gevaert; N Bovenschen
Journal:  Cell Death Differ       Date:  2013-11-01       Impact factor: 15.828

8.  Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death.

Authors:  Pieter J A de Koning; J Alain Kummer; Stefanie A H de Poot; Razi Quadir; Roel Broekhuizen; Anne F McGettrick; Wayne J Higgins; Bart Devreese; D Margaret Worrall; Niels Bovenschen
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

9.  Toward the next generation of NK cell-based adoptive cancer immunotherapy.

Authors:  Jing Ni; Matthias Miller; Ana Stojanovic; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

10.  Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

Authors:  Jing Ni; Matthias Miller; Ana Stojanovic; Natalio Garbi; Adelheid Cerwenka
Journal:  J Exp Med       Date:  2012-12-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.